1 / 37

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV)

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV). Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University. Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV). Fuad AM Hasan Department Of Medicine Faculty of Medicine

makani
Download Presentation

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University

  2. Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University

  3. Current And Future Treatment of HCV:The Count Down To The Demise of Hepatology Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University

  4. True or False • Hepatitis C is incurable. Treatment only suppresses the virus • Interferon and ribavirin therapy are associated with minor adverse events • HCV genotype is a major determinant of response to interferon based therapy. • Boceprevir and telaprevir are effective against all genotypes. • Sofosbuvir in combination with IFN and ribavirin cures around 90% of HCV infected patients

  5. Outline • HCV structure and life cycle • HCV genotypes • Standard treatment of HCV (2001-2011) • Standard treatment of HCV genotype 1 (2011-2013) • Current treatment of HCV genotypes 1-6 • The future

  6. HCV Polyprotein Processing and Viral Protein Function McGovern B, Abu Dayyeh B, and Chung RT. Hepatology. 2008; 48:1700-12

  7. HCV Life Cycle and DAA Targets Receptor bindingand endocytosis Transportand release Fusion and uncoating LD LD Translation andpolyprotein processing ER lumen Virionassembly (+) RNA LD NS3/4 protease inhibitors NS5B polymerase inhibitors Nucleoside/nucleotide Nonnucleoside Membranousweb RNA replication ER lumen NS5A inhibitors Block replication complex formation, assembly RNA replication Adapted from Manns MP, et al. Nat Rev Drug Discov. 2007;6:991-1000.

  8. HCV Genotypes

  9. The Prevalence of HCV Genotype 4 in Kuwait Hasan et al. Hepatogastroenterology2002 * Eastern province of Syria

  10. Seroprevalence of HCV in Kuwait Ameen R et al. Transfusion. 2005 ;45:1973-80. Chehada W et al. J infect Public Health 2011 ;4:200-6 *Al Khalidi J et al. Unpublished data

  11. Treatment of HCV 2001-2011 Pegylated Interferon plus Ribavirin combination was the standard treatment of HCV regardless of genotype until 2011

  12. Sustained Virologic Responses By Genotype *Hasan F, et al. Am J Gastroenterol 2004;99:1733-1737

  13. Interferon Plus Ribavirin TherapyLimitations 20-60 % do not respond Numerous side effects

  14. Factors That Influence Response to Interferon Based Therapy Treatment regimen PEG-IFN Ribavirin DAA Host factors Age, gender, race obesity, co-morbidities Genetic factors (IL28B and ITPA) Factors that affect outcome Disease features Fibrosis, steatosis, co-infection (HBV, HIV) Viral factors Genotype / Subtype Quasispecies / Resistance Viral load

  15. Most Important Factors that Influence Treatment Outcome HCV Genotype IL 28 B Polymorphism Degree of Fibrosis HCV RNA level

  16. Side Effects of PegIFN/Ribavirin Fever Myalgias Hair loss Depression Anemia Rash “Interferon Man” Many others !

  17. Was it the Interferon Man ?

  18. Contraindications of Pegylated Interferon and Ribavirin • De-compensated cirrhosis • Coronary artery disease, heart failure, serious dysrythmia • Proliferative diabetic retinopathy • Kidney transplant patients • Renal impairment (ribavirin)

  19. 2011: Telaprevir and Boceprevir for HCV Genotype 1

  20. Sustained Virologic Response: Telaprevir plus Peg Interferon Plus Ribavirin PR 74–79* PR48 166/361 T12/PR 683/903 n/N = *p<0.0001 T12/PR vs PR48 (79% versus 46%) in ADVANCESVR, considered virologic cure, was defined as HCV RNA <25 IU/mL at last observation within the Week 72 visit window. In case of missing data, the last HCV RNA data point from Week 12 of follow-up onwards was used INCIVO (telaprevir) EU SmPC

  21. SVR rates with boceprevir plus PR versus PR alone * * PR48 137/363 BOC RGT 233/368 BOC44/PR48 242/366 n/N = *p<0.001 for both boceprevir arms versus PR48 SVR was defined as undetectable HCV RNA at the last available value in the period at or after follow-up Week 24. If there was no such value, the follow-up Week value was carried forward VICTRELIS (boceprevir) EU SmPC

  22. Adverse Events with Telapravir and Bocepravir

  23. Important Safety Information Contraindicated Drugs and Other Precautions for Telaprevir *These interactions have been studied; †Impaired renal/hepatic function; ‡No clinical data are available regarding the treatment of organ transplant patients with TRADENAME in combination with peg-IFN/RBV. Therefore, the use of TRADENAME in organ transplant patients is not recommended; §Normal renal/hepatic function.

  24. December 2013Simeprevir and Sofosbuvir

  25. Efficacy With Simeprevir + P/R in Tx-Naive GT1 Patients: Phase III Trials • SMV + P/R for 12 wks followed by 12-36 wks of P/R (placebo control) Simeprevir + P/R Placebo + P/R 100 100 82 85 84 80 80 80 58 58 53 60 60 53 52 50 43 SVR (%) 40 40 29 20 20 419/521 133/264 138/165 36/83 49/84 23/44 228/267 70/133 188/229 60/113 18/31 5/17 n/N = n/N = 0 0 Overall GT1aWithoutQ80K GT1a WithQ80K GT1b No Cirrhosis Cirrhosis Jacobson I, et al. EASL 2013. Abstract 1425.

  26. Simeprevir Is Well Tolerated Bilirubin Hemoglobin 200 30 180 20 SMV + P/RP/R SMV + P/RP/R 160 Mean (µmol/L) Mean (µmol/L) 140 10 120 100 0 0 2 4 8 12 16 20 24 36 48 0 2 4 8 12 16 20 24 36 48 Wks Wks • Mild unconjugatedhyperbilirubinemia→ transporter • No anemia signal beyond P/R • Rash up to 25% (mild) Manns M, et al. EASL 2013. Abstract 1413.

  27. Efficacy With Sofosbuvir + P/R in Tx-Naive GT1/4/5/6 Patients: Phase III Trials • Single-arm study of sofosbuvir + P/R for 12 wks SVR12 According to GT SVR12 According to Fibrosis Level 100 96 100 100 92 89 80 80 80 60 60 SVR12 (%) SVR12 (%) 40 40 20 20 n/N = 261/292 27/28 7/7 252/273 43/54 0 0 GT1 GT4 GT5/6 No Cirrhosis Cirrhosis Lawitz E, et al. N Engl J Med. 2013;368:1878-1887.

  28. Efficacy of Sofosbuvir in GT2 Treatment Naive[1] Treatment Experienced[2] 12 wks of SOF + RBV PegIFN/RBV 16 wks of SOF + RBV 100 98 96 100 100 91 82 78 80 80 62 60 60 60 SVR12 (%) 40 40 20 20 n/N = 25/26 23/23 6/10 7/9 n/N = 58/59 44/54 10/11 8/13 0 0 No Cirrhosis Cirrhosis No Cirrhosis Cirrhosis 1. Gane E, et al. EASL 2013. Abstract 5.2. Jacobson I, et al. N Engl J Med. 2013;368:1867-1877. GT2

  29. FDA Approved Indications for Sofosbuvir

  30. DO NOT USE TELAPREVIR OR BOCEPREVIR

  31. The FutureInterferon Free Regimens

  32. IFN-Free Therapy for Tx-Naive GT1 HCV C-WORTHY12-wk regimens[4] AVIATOR[1] ABT-450/RTV + ABT-333 + ABT-267 + RBV LONESTAR[2] AI443-014[3] Daclatasvir + Asunaprevir + BMS-791325for 12 wks SOF/LDV FDC 8 wks MK-5172 + MK-8742 20 mg + RBV SOF/LDV + RBV 8 wks MK-5172 + MK-8742 50 mg + RBV 24 wks SOF/LDV FDC 12 wks 12 wks MK-5172 + MK-8742 50 mg 100 100 95 95 100 96 96 100 100 100 92 90 89 80 80 80 80 60 60 60 60 SVR12/24 (%) 40 40 40 40 20 20 20 20 n = 77 21 19 20 80 27 13 79 25 0 0 0 0 1. Kowdley K, et al. EASL 2013. Abstract 3. 2. Lawitz E, et al. AASLD 2013. Abstract 215. 3. Everson GT, et al. AASLD 2013. Abstract LB-1. 4. Lawitz E, et al. AASLD 2013. Abstract 76.

  33. Is the demise of Hepatology imminent ? • HCV cure rate approaching 95% • HBV incidence declining rapidly due to vaccination • Treatment of HBV and HCV using direct acting antivirals is safe, simple and can be handled by internists. • Alcoholic liver disease and NASH can be handled by internists • Only end stage liver disease and liver transplant patients need specialty care ?

More Related